iBio, Inc. (IBIO)

Last Closing Price: 0.75 (2023-06-02)

Company Description

Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture of proteins applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus and veterinary influenza applications. IBio, Inc. is headquartered in Newark, Delaware.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $2.38M
Net Income (Most Recent Fiscal Year) $-50.30M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 4.45
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.68
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -11133.67%
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -150.09%
Return on Assets (Trailing 12 Months) -79.33%
Current Ratio (Most Recent Fiscal Quarter) 1.22
Quick Ratio (Most Recent Fiscal Quarter) 1.22
Debt to Common Equity (Most Recent Fiscal Quarter) 0.04
Inventory Turnover (Trailing 12 Months) 0.22
Book Value per Share (Most Recent Fiscal Quarter) $7.27
Earnings per Share (Most Recent Fiscal Quarter) $-1.08
Earnings per Share (Most Recent Fiscal Year) $-5.78
Diluted Earnings per Share (Trailing 12 Months) --
Exchange NYSEMKT
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 16.80M
Free Float 16.40M
Market Capitalization $12.56M
Average Volume (Last 20 Days) 0.19M
Beta (Past 60 Months) -3.19
Percentage Held By Insiders (Latest Annual Proxy Report) 2.38%
Percentage Held By Institutions (Latest 13F Reports) --
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%